Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Brief Communication
  • Published:

De novo nonsense mutations in ASXL1 cause Bohring-Opitz syndrome

Subjects

Abstract

Bohring-Opitz syndrome is characterized by severe intellectual disability, distinctive facial features and multiple congenital malformations. We sequenced the exomes of three individuals with Bohring-Opitz syndrome and in each identified heterozygous de novo nonsense mutations in ASXL1, which is required for maintenance of both activation and silencing of Hox genes. In total, 7 out of 13 subjects with a Bohring-Opitz phenotype had de novo ASXL1 mutations, suggesting that the syndrome is genetically heterogeneous.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Clinical presentation of subjects with Bohring-Opitz syndrome and ASXL1 mutations.

Similar content being viewed by others

Accession codes

Accessions

GenBank/EMBL/DDBJ

References

  1. Oberklaid, F. & Danks, D.M. Am. J. Dis. Child. 129, 1348–1349 (1975).

    Article  CAS  Google Scholar 

  2. Hastings, R., Cobben, J.M. & Gillessen-Kaesbach, G. et al. Eur. J. Hum. Genet. 19, 513–519 (2011).

    Article  CAS  Google Scholar 

  3. Bohring, A., Oudesluijs, G.G., Grange, D.K., Zampino, G. & Thierry, P. Am. J. Med. Genet. A. 140, 1257–1263 (2006).

    Article  Google Scholar 

  4. Ng, S.B. et al. Nat. Genet. 42, 790–793 (2010).

    Article  CAS  Google Scholar 

  5. Gilissen, C. et al. Am. J. Hum. Genet. 87, 418–423 (2010).

    Article  CAS  Google Scholar 

  6. Hoischen, A. et al. Nat. Genet. 42, 483–485 (2010).

    Article  CAS  Google Scholar 

  7. Kaname, T. et al. Am. J. Hum. Genet. 81, 835–841 (2007).

    Article  CAS  Google Scholar 

  8. Bisgaard, A.M. et al. Eur. J. Med. Genet. 50, 243–255 (2007).

    Article  Google Scholar 

  9. Fisher, C.L. et al. Dev. Biol. 337, 9–15 (2010).

    Article  CAS  Google Scholar 

  10. Kleefstra, T., Nillesen, W.M. & Yntema, H.G. GeneReviews (eds Pagon, R.A., Bird, T.D., Dolan, C.R. & Stephens, K.) (University of Washington, Seattle, Washington, USA, 1993–2010 ).

  11. Gelsi-Boyer, V. et al. Br. J. Haematol. 151, 365–375 (2010).

    Article  CAS  Google Scholar 

  12. Boultwood, J. et al. Leukemia 24, 1062–1065 (2010).

    Article  CAS  Google Scholar 

  13. Bench, A.J. et al. Oncogene 19, 3902–3913 (2000).

    Article  CAS  Google Scholar 

  14. Rodríguez-Santiago, B. et al. Am. J. Hum. Genet. 87, 129–138 (2010).

    Article  Google Scholar 

Download references

Acknowledgements

We thank the subjects and their parents for participation in this study. We thank P. Arts, M. Steehouwer and personnel from the Microarray Facility and Sequencing Facility Nijmegen for technical assistance. We thank N. Wieskamp, J. de Ligt and M. Rosario for bioinformatics support in data analysis. The authors are grateful to M. Sipponen and J. Ignatius for collaborative efforts relating to patient 4 and to C. Fisher for information on the Asxl1 knockout mouse. This study was financially supported by the Netherlands Organization for Health Research and Development (ZonMW grants 917-66-36 and 911-08-025 to J.A.V., 916-86-016 to L.E.L.M.V. and 917-86-319 to B.B.B.A.d.V.), the EU-funded TECHGENE project (Health-F5-2009-223143 to J.A.V.) and the AnEUploidy project (LSHG-CT-2006-37627 to A.H., B.W.M.v.B., H.G.B., B.B.B.A.d.V. and J.A.V.). The Family Federation of Finland is funded by Finland's Slot Machine Association (RAY). B. R.-S. was supported by a postdoctoral fellowship of the Fondo Investigación Sanitaria, Spain (FIS CD06/00019).

Author information

Authors and Affiliations

Authors

Contributions

A.H., B.W.M.v.B., B.R.-S., H.G.B., B.B.B.A.d.V. and J.A.V. conceived the project and planned the experiments. B.W.M.v.B., H.G.B. and B.B.B.A.d.V. performed review of phenotypes and sample collection. H.G.B., R.H., S.F.S., R.N.-E., S.K., J.G., R.M., D.B., A.R., M.P., J.M.C., D.W. and G.G.-K. clinically characterized the Bohring-Opitz syndrome cases and collected blood samples. A.H., L.E.L.M.V., P.d.V., I.J. and B.v.L. performed next-generation sequencing experiments. P.d.V. and B.v.L. performed validation experiments. C.G., B.R.-S. and A.H. analyzed and interpreted the data. All authors contributed to the final manuscript.

Corresponding author

Correspondence to Han G Brunner.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Text and Figures

Supplementary Tables 1–3, Supplementary Figures 1 and 2 and Supplementary Note. (PDF 1080 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hoischen, A., van Bon, B., Rodríguez-Santiago, B. et al. De novo nonsense mutations in ASXL1 cause Bohring-Opitz syndrome. Nat Genet 43, 729–731 (2011). https://doi.org/10.1038/ng.868

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ng.868

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing